nonclinical safety assessment for small molecules and biologic drug development (6of14) redi 2018
Published 4 years ago • 12K plays • Length 44:31Download video MP4
Download video MP3
Similar videos
-
54:28
overview of non-clinical assessment in drug development (8/14) redi 2017
-
31:53
getting to first-in-human for small molecules and biologics
-
37:34
designing first-in-human trials for small molecules and biologics
-
5:47
how biomarkers can improve the drug development process
-
35:51
orange book exclusivity: part ii - pediatric, orphan, and gain
-
46:00
introduction to investigational new drug (ind) applications (3/14) redi 2017
-
43:14
introduction to regulatory science at the fda
-
31:21
benefit-risk considerations in drug development (6/14) redi 2017
-
20:09
regulated bioanalysis of large molecules - bioanalysis 2020
-
18:21
assembling the best team to navigate through preclinical development
-
25:35
application of (q)sar and expert knowledge for ich m7 impurity classification
-
5:20
data requirements for biosimilars
-
36:51
investigational new drug safety reporting requirements (10of14) redi 2018